Down 11.8% today, more than its organic chemicals peers' 2.6%; no story names it yet.
Lags the market
Down 97% over five years while the S&P 500 rose 76%.
CDXS's Quality Score fell 1 point on Mon, Nov 2, to -4.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Latest filing | 10-Q, Aug 11 |
TodayNo story names it yet.
Tue Nov 3: TIDES Europe 2026Industry event · date confirmed.
After its last 4 reports it closed +9.1% on average, higher 3 of 4 times.
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. CDXS scores -4 today, against a median of 0 over its last 20 recorded sessions.
CDXS is #11 of 15 by Quality Score among Industrial Organic Chemicals.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 11 |
Reports Thu Nov 12, after the close (in 10 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease was primarily due to lower employee-related costs, reduced spending on outside services and lower lab supplies, partially offset by higher allocable costs.”
CDXS's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenues | $72M to $76M |
“Gross margin for the year 2026 is expected to be in the high 60% range.”
From its results filing (SEC filing · Aug 11)
Sales grew 0.4% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 8% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 11, 2026 | +0.7% | +8.1% | +1.4% |
| May 7, 2026 | +0.8% | +10.5% | -0.4% |
| Mar 11, 2026 | +52.0% | +34.6% | +15.8% |
Sales grew in five of the last seven years, to $70.4M in 2025. It lost money in each of the eight years.
3 insiders sold $23K across 3 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CDXS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
CDXS scores -4 today, which Breakaway calls Poor. It is #11 of 15 in Industrial Organic Chemicals by Quality Score, with 1 of 14 chart checks firing. Down 97% over five years while the S&P 500 rose 76%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CDXS scores -4 today, which Breakaway calls Poor (below zero). That is #11 of 15 in Industrial Organic Chemicals by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CDXS's -4.
3 insiders sold $23K across 3 filings in the last 6 months. No open-market buys on record. The newest is Georgia Erbez, Insider, who sold $9K on Oct 12. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.